ArticleBlood2014
Postartesunate delayed hemolysis is a predictable event related to the lifesaving effect of artemisinins.
Article in Blood, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 78 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
78 citing papers in PubMed, 1 synthesis or guideline pooled it, 149 citations in OpenAlex.
- Systematic analysis of direct antiglobulin test results in post-artesunate delayed haemolysis.Malaria journal · 2021Pooled it
- AQ-13, an investigational antimalarial, versus artemether plus lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria: a randomised, phase 2, non-inferiority clinical trial.The Lancet. Infectious diseases · 2017Trial
- Post-treatment haemolysis in African children with hyperparasitaemic falciparum malaria; a randomized comparison of artesunate and quinine.BMC infectious diseases · 2017Trial
- Clinical illness and outcomes in Nigerian children with late-appearing anaemia after artemisinin-based combination treatments of uncomplicated falciparum malaria.BMC infectious diseases · 2016Trial
- Intramuscular Artesunate for Severe Malaria in African Children: A Multicenter Randomized Controlled Trial.PLoS medicine · 2016Trial
- Temporal changes in haematocrit following artemisinin-based combination treatments of uncomplicated falciparum malaria in children.BMC infectious diseases · 2015Trial
- Urinary carbonic anhydrase 1 excretion is a marker of hemolysis-triggering conditions suitable for point-of-care testing.Blood global hematology · 2026Article
- The usual suspect-malaria? Diagnostic challenges in post-artesunate delayed haemolysis: a clinical laboratory perspective through a case report.Malaria journal · 2025Review
- From sixty-four percent hyperparasitemia to recovery: Managing severe falciparum malaria and delayed hemolytic anemia.IJID regions · 2025Article
- Role of channels in the ObioRxiv : the preprint server for biology · 2025Article
- Whole blood exchange ameliorates acute hemolytic anemia by reducing inflammation and oxidative stress in rats.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025Article
- Post-Artesunate Delayed Hemolysis in Pediatric Malaria Patients in the United States.Journal of the Pediatric Infectious Diseases Society · 2024Article
- Article
- Acute Kidney Injury and Post-Artesunate Delayed Haemolysis in the Course ofPathogens (Basel, Switzerland) · 2024Article
- Retention of uninfected red blood cells causing congestive splenomegaly is the major mechanism of anemia in malaria.American journal of hematology · 2024Article
- Review
- Article
- Delayed Hemolysis With Parenteral Artesunate.Hospital pharmacy · 2023Article
- Post-treatment haemolysis is common following oral artemisinin combination therapy of uncomplicated malaria in travellers.Journal of travel medicine · 2023Observational
- Plasmodium falciparum-Induced Autoimmune Hemolytic Anemia in a Pregnant Patient with Sickle Cell Disease.The American journal of case reports · 2023Article
18 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
21 authors at 6 institutions in 2 countries.
Funding
Abstract
Patients with severe malaria treated with artesunate sometimes experience a delayed hemolytic episode. Artesunate (AS) induces pitting, a splenic process whereby dead parasites are expelled from their host erythrocytes. These once-infected erythrocytes then return to the circulation. We analyzed hematologic parameters in 123 travelers treated with AS for severe malaria. Among 60 nontransfused patients observed for more than 8 days, 13 (22%) had delayed hemolysis. The peak concentration of circulating once-infected erythrocytes was measured during the first week in 21 patients and was significantly higher in 9 patients with delayed hemolysis than in 12 with other patterns of anemia (0.30 vs 0.07; P = .0001). The threshold of 180 million once-infected erythrocytes per liter discriminated patients with delayed hemolysis with 89% sensitivity and 83% specificity. Once-infected erythrocyte morphology analyzed by using ImageStream in 4 patients showed an 8.9% reduction in their projected area, an alteration likely contributing to their shorter lifespan. Delayed clearance of infected erythrocytes spared by pitting during AS treatment is an original mechanism of hemolytic anemia. Our findings consolidate a disease framework for posttreatment anemia in malaria in which delayed hemolysis is a new entity. The early concentration of once-infected erythrocytes is a solid candidate marker to predict post-AS delayed hemolysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.